Similar Search Results

Can branded drugs benefit from generic entry? : the role of detailing and price in switching to non-bioequivalent molecules

Gonzalez, Jorge; Sismeiro, Catarina; Dutta, Shantanu; … - In: International journal of research in marketing : IJRM ; … 25 (2008) 4, pp. 247-260

Persistent link: https://www.econbiz.de/10003793502

Drug competition : the Waxman-Hatch act revisited

Virabhak, Suchin; Sohn, Wook - In: Journal of pharmaceutical finance, economics & policy 15 (2006) 2, pp. 3-20

Persistent link: https://www.econbiz.de/10003462659

Generic competition and market exclusivity periods in pharmaceuticals

Grabowski, Henry G.; Kyle, Margaret K. - In: Managerial and decision economics : MDE ; the … 28 (2007) 4/5, pp. 491-502

Persistent link: https://www.econbiz.de/10003543732

Essays on the economics of pharmaceuticals

Virabhak, Suchin - 2005

Persistent link: https://www.econbiz.de/10003550944

Perspective : the evolution of R&D conduct in the pharmaceutical industry

Schramm, Mary E.; Hu, Michael Y. - In: The journal of product innovation management : an … 30 (2013), pp. 203-213

Persistent link: https://www.econbiz.de/10010211442

Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets

Conti, Rena M. - 2019

We establish four facts concerning competition among U.S. generic drug suppliers, using IQVIA's National Sales … cohorts; (iii) the extent of competition is greatest for the oldest molform cohorts and is smallest for the youngest molform … cohorts. With a median of one competitor, the extent of competition in the youngest molform cohort is very limited; and (iv …

Persistent link: https://www.econbiz.de/10012480138